Skip to main content
SpringerLink
Log in

58/w mit Unterbauchschmerzen, Inappetenz und Völlegefühl

Vorbereitung auf die Facharztprüfung: Fall 6

58/f with lower abdominal pain, loss of appetite, and bloating

Preparation for the medical specialist examination: part 6

  • Facharzt-Training
  • Published:
best practice onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Casali PG et al (2018) Gastrointestinal stromal tumours: ESMO 2013; EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv68–iv78

    Article  CAS  Google Scholar 

  2. Fletcher CD et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33(5):459–465

    Article  Google Scholar 

  3. Corless CL, Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 11(12):865–878

    Article  CAS  Google Scholar 

  4. Szucs Z et al (2017) Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol 13(1):93–107

    Article  CAS  Google Scholar 

  5. Casali PG et al (2017) Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for research and treatment of cancer, Italian Sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on Imatinib at two dose levels. J Clin Oncol 35(15):1713–1720

    Article  Google Scholar 

  6. Garner AP et al (2014) Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res 20(22):5745–5755. https://doi.org/10.1158/1078-0432.CCR-14-1397

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Evans E et al (2015) Abstract 791: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants. Cancer Res 75:791–791

    Article  Google Scholar 

  8. Heinrich MC et al (2020) Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 21(7):935–946

    Article  CAS  Google Scholar 

  9. Falchook GS et al (2013) BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 4(2):310–315

    Article  CAS  Google Scholar 

  10. Bauer S et al (2005) Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117(2):316–325

    Article  CAS  Google Scholar 

  11. Wardelmann E et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6(4):249–251

    Article  CAS  Google Scholar 

  12. Bauer S et al (2014) Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib—analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 40(4):412–419. https://doi.org/10.1016/j.ejso.2013.12.020

    Article  CAS  PubMed  Google Scholar 

  13. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23(2):70–83

    Article  Google Scholar 

  14. Joensuu H et al (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13(3):265–274

    Article  Google Scholar 

  15. Wozniak A et al (2014) Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: A European multicenter analysis based on ConticaGIST. Clin Cancer Res 20(23):6105–6116. https://doi.org/10.1158/1078-0432.CCR-14-1677

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sarkomzentrum am Westdeutschen Tumorzentrum, Innere Klinik (Tumorforschung), Universitätsklinikum Essen, Essen, Deutschland

    Johanna Falkenhorst & Sebastian Bauer

Authors
  1. Johanna Falkenhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sebastian Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johanna Falkenhorst.

Ethics declarations

Interessenkonflikt

J. Falkenhorst: Honorare: Pharmamar; Reisekosten: Eli Lilly, Pharmamar. S. Bauer: Honorare/Finanzierung wissenschaftlicher Untersuchungen: Novartis, Blueprint Medicines; Honorare: Deciphera, Bayer, Exelixis, Daichii-Sankyo, Plexxikon; Finanzierung wissenschaftlicher Untersuchungen: Incyte.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patienten zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.

Additional information

Redaktion

M. Christopeit, Tübingen

C. Oing, Hamburg

K. Höffken, Düsseldorf

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Falkenhorst, J., Bauer, S. 58/w mit Unterbauchschmerzen, Inappetenz und Völlegefühl. best practice onkologie 17, 434–444 (2022). https://doi.org/10.1007/s11654-022-00415-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-022-00415-2

Schlüsselwörter

Search

Navigation